Stay updated with breaking news from Nasdaq dmac. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) will be issuing its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link. DiaMedica Therapeutics (NASDAQ:DMAC […]
Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Free Report) were up 0.7% during mid-day trading on Thursday . The company traded as high as $3.02 and last traded at $2.91. Approximately 44,769 shares traded hands during trading, a decline of 42% from the average daily volume of 77,022 shares. The stock had previously closed […]
DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Free Report) shares fell 8.6% on Monday . The company traded as low as $2.50 and last traded at $2.56. 183,312 shares changed hands during trading, an increase of 113% from the average session volume of 85,998 shares. The stock had previously closed at $2.80. Wall Street Analyst Weigh […]
DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Monday, August 14th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last announced its quarterly earnings data on Monday, May 15th. The […]
DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Free Report) was the target of a large growth in short interest in July. As of July 15th, there was short interest totalling 796,100 shares, a growth of 11.6% from the June 30th total of 713,600 shares. Approximately 4.5% of the shares of the stock are sold short. Based […]
DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Rating) Director Randall Michael Giuffre acquired 65,000 shares of DiaMedica Therapeutics stock in a transaction that occurred on Friday, June 23rd. The shares were bought at an average price of $3.91 per share, with a total value of $254,150.00. Following the transaction, the director now directly owns 360,355 shares […]
DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Rating) insider David J. Wambeke purchased 38,364 shares of the stock in a transaction on Friday, June 23rd. The stock was acquired at an average cost of $3.91 per share, with a total value of $150,003.24. Following the acquisition, the insider now owns 507,114 shares of the company’s stock, […]
DiaMedica Therapeutics (NASDAQ:DMAC – Get Rating) was upgraded by analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a report released on Thursday, The Fly reports. The brokerage currently has a $7.00 target price on the stock. Oppenheimer’s price target points to a potential upside of 64.71% from the company’s previous […]
DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Rating) was the target of a significant drop in short interest in April. As of April 30th, there was short interest totalling 91,900 shares, a drop of 5.6% from the April 15th total of 97,400 shares. Based on an average daily trading volume, of 27,100 shares, the days-to-cover ratio […]
DiaMedica Therapeutics (NASDAQ:DMAC – Get Rating) and Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation. Volatility and Risk DiaMedica Therapeutics has a beta of […]